𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A pilot study of 2 years of interferon treatment in patients with chronic delta hepatitis

✍ Scribed by C. Yurdaydın; H. Bozkaya; H. Karaaslan; F. O. Önder; Ö. E. Erkan; K. Yalçın; H. Değertekin; A. M. Bozdayı; Ö. Uzunalimoğlu

Book ID
108886030
Publisher
John Wiley and Sons
Year
2007
Tongue
English
Weight
89 KB
Volume
14
Category
Article
ISSN
1352-0504

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Treatment of children with chronic hepat
Treatment of children with chronic hepatitis C with recombinant interferon-α: A pilot study
✍ Mercedes Ruiz-Moreno; Maria José Rua; Inmaculada Castillo; Maria Dolores García- 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 424 KB 👁 1 views

Twelve children with chronic non-A, non-B hepatitis were entered in a pilot trial of recombinant interferon-alpha. Although all the children had hepatitis C virus RNA in serum, only five had antibodies against this virus. Children received 3 MU/m2 body surface area interferon-alpha 3 times/wk for 6

A pilot study of corticosteroid priming
A pilot study of corticosteroid priming for lymphoblastoid interferon alfa in patients with chronic hepatitis C
✍ K Chayama; A Tsubota; M Kobayashi; M Hashimoto; Y Miyano; H Koike; M Kobayashi; 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 183 KB 👁 2 views

These factors are important, because they may influpolymerase chain reaction. ence the outcome of treatment. Furthermore, the study From the Department of Gastroenterology, Toranomon Hospital, Okinaka did not evaluate the effect of treatment on HCV clear-Memorial Institute for Medical Research, Tor

Treatment of chronic non-A, non-B hepati
Treatment of chronic non-A, non-B hepatitis with acyclovir: Pilot study
✍ S. Chris Pappas; Dr. Jay H. Hoofnagle; Neal Young; Stephen E. Straus; E. Anthony 📂 Article 📅 1985 🏛 John Wiley and Sons 🌐 English ⚖ 576 KB

Five patients with chronic non-A, non-B hepatitis were entered into a pilot therapeutic study of the antiviral agent acyclovir [9-(2-hydroxyethoxymethyl) guanine]. Each patient received acyclovir by slow intravenous infusion in a dosage of 5 mg/kg every 8 hr for 10 days. During therapy, serum aminot

A pilot study of recombinant interleukin
A pilot study of recombinant interleukin-2 for treatment of chronic hepatitis C
✍ M Pardo; I Castillo; H Oliva; A Fernandez-Flores; R Barcena; M A de Peuter; V Ca 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 178 KB 👁 1 views

The optimal and safer interleukin-2 (IL-2) dose for treatment of chronic hepatitis C virus (HCV) infection has been studied in 33 HCV-RNA positive patients with chronic hepatitis C. Patients were randomly allocated to receive 5 days per week during 12 weeks IL-2 doses of: 0.9 MIU (n = 10), 1.8 MIU (